# Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

> **NCT03890302** · PHASE1 · COMPLETED · sponsor: **Fountain Biopharma Inc.** · enrollment: 31 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** FB704A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03890302
- **Lead sponsor:** Fountain Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-14
- **Primary completion:** 2020-05-27
- **Final completion:** 2020-05-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890302, "Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03890302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*